SCHEMBL16748446

SCHEMBL16748446

CCc1nc2c(F)cccc2n1-c1nc(N)nc(Nc2ccc(Cl)c(F)c2)n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
NOD1 Q9Y239 1/20 0.37
USP2 O75604 4/20 0.37
HSD17B10 Q99714 1/20 0.37
MAPT P10636 3/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
PIK3CA P42336 2/20 0.36
MTOR P42345 2/20 0.36
XBP1 P17861 1/20 0.36
MAPK1 P28482 1/20 0.36
AURKA O14965 1/20 0.36
AURKB Q96GD4 1/20 0.36
CYBB P04839 2/20 0.36
NOX4 Q9NPH5 2/20 0.36
NOX1 Q9Y5S8 2/20 0.36
NOX5 Q96PH1 1/20 0.36
NOX3 Q9HBY0 1/20 0.36
FFAR1 O14842 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16740774 0.89 AGPAT2 (0.39) NPC1RAB9AUSP2MAPTMAPK1
SCHEMBL16748425 0.89 MAPK1 (0.36) USP2MAPTMEN1KMT2AXBP1
SCHEMBL16740735 0.88 PIK3CA (0.44) PIK3CAMTORPIK3CDPIK3CBPIK3CG
SCHEMBL16748433 0.87 MAPT (0.46) NPC1RAB9AUSP2HSD17B10MAPT
SCHEMBL16740729 0.85 AGPAT2 (0.39) NPC1RAB9AUSP2HSD17B10MAPT
SCHEMBL16740828 0.85 AGPAT2 (0.36) USP2MAPTPIK3CAMTORMAPK1
SCHEMBL16740781 0.85 BMI1 (0.38) NPC1RAB9ANOD1USP2HSD17B10
SCHEMBL16740821 0.84 BMI1 (0.46) USP2MAPTALDH1A1HTTTDP1
SCHEMBL16748432 0.84 SLC29A2 (0.47) NPC1RAB9AMAPTMEN1KMT2A
SCHEMBL16740806 0.84 MAPT (0.37) NPC1RAB9AUSP2HSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US claimed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US claimed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
WO-2015076801-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. (US) 2015-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS BMI1, BAZ2A, BAZ2B NPC1 2824/4885RAB9A 3670/4885NOD1 1018/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.